Key points are not available for this paper at this time.
Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite-instable, metastatic disease, anti- programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.
Building similarity graph...
Analyzing shared references across papers
Loading...
Rebecca Brooks
Gini F. Fleming
Ricardo R. Lastra
CA A Cancer Journal for Clinicians
Harvard University
University of Chicago
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Brooks et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69de95be1d9bba5129b0c56c — DOI: https://doi.org/10.3322/caac.21561